IMMUNOS THERAPEUTICS
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
IMMUNOS THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2014-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.immunostherapeutics.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
90.48 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins Sitelinks Search Box Microsoft Exchange Online
Similar Organizations
ACS Biotech
ACS Biotech is an innovative start up in biotechnology
Annexin Pharmaceuticals
Annexin Pharmaceuticals AB (publ) is a world-leading biotechnology company.
Benchmark Holdings
Benchmark Holdings, a pioneering bioagtech company.
Biogenera
BIOGENERA SpA is a company operating in the biotechnology pharmaceutical sector.
Biorem Inc.
Biorem is a pioneer environmental biotechnology company.
Biotherapeutics
BioTherapeutics Inc. (BTI) is a pre-clinical stage company
CellmAbs
Pharmaceutical Company, Biotechnology
Chemotargets
Chemotargets is a computationally-oriented biotech company
Cloudbreak Therapeutics
Cloudbreak Therapeutics is a clinical stage biotechnology company
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Destiny Pharma
Destiny Pharma Ltd., a clinical stage pharmaceutical company
DiscoveryBioMed
DiscoveryBioMed, Inc. (DBM) is a life sciences and biotechnology company,
Emendo Biotherapeutics
Emendo Biotherapeutics is a biotechnology company
Enthera
Enthera is a biotech company whose mission is to find new therapeutic approaches to treat diabetes and gastrointestinal complication.
Ogeda
Ogeda is a privately owned clinical-stage drug discovery company.
Genmedica Therapeutics
Genmedica Therapeutics is a development-stage biotechnology company focused on type 2 diabetes.
Chance Pharmaceuticals
Chance Pharmaceuticals is a clinical-stage biotechnology company focusing on discovering.
Hebei Daan Pharmaceutical Co., Ltd
Hebei Daan Pharmaceutical Co., Ltd is a blood product manufacturing company.
Iltoo Pharma
ILTOO Pharma is a clinical-stage biotechnology company
Ingenza
Ingenza is an industrial biotechnology company.
LinKinVax
LinKinVax operates as a clinical-stage biotechnology company.
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
MaxiVAX
MaxiVAX is a Swiss clinical-stage biotechnology company.
Metera Pharmaceuticals
Metera Pharmaceuticals is a preclinical stage biotechnology company.
OliX Pharmaceuticals
OliX is a clinical stage biotechnology company.
PositiveID
PositiveID is a life science and technology company.
Pulmobiotics
Pulmobiotics is a pre-clinical life sciences company.
Quell Therapeutics
Quell Therapeutics is a cell therapy company
Rain Therapeutics
Rain Therapeutics is a operator of a clinical stage biotechnology company.
RetiPharma
RetiPharma is a Danish Biotech company
SagaNatura
SagaNatura is a dynamic Icelandic biotech company.
Step Pharma
Step Pharma is a biotechnology company.
Summit Therapeutics
Summit Therapeutics is a clinical-stage drug discovery and development company.
The Brain Protection Company
The Brain Protection Company is a clinical-stage company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
TheraSource
TheraSource is a growing biotech company
UTC Therapeutics
UTC Therapeutics’s vision is to become the leading global biotechnology company
Current Advisors List
Current Employees Featured
Founder
Investors List
Schroder Adveq
Schroder Adveq investment in Series B - ImmunOs Therapeutics
BioMedPartners
BioMedPartners investment in Series B - ImmunOs Therapeutics
Mission BioCapital
Mission BioCapital investment in Series B - ImmunOs Therapeutics
Pfizer Venture Investments
Pfizer Venture Investments investment in Series B - ImmunOs Therapeutics
PEAK6 Investments LLC
PEAK6 Investments LLC investment in Series B - ImmunOs Therapeutics
Fiscus Financial
Fiscus Financial investment in Series B - ImmunOs Therapeutics
Samsara BioCapital
Samsara BioCapital investment in Series B - ImmunOs Therapeutics
GL Capital
GL Capital investment in Series B - ImmunOs Therapeutics
Lightspeed Venture Partners
Lightspeed Venture Partners investment in Series B - ImmunOs Therapeutics
Gimv
Gimv investment in Series B - ImmunOs Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-01 | ImmunOs Therapeutics Appoints Jeffrey Abbey as Chief Operating Officer, Establishes Clinical Advisory Board |
Official Site Inspections
http://www.immunostherapeutics.com
- Host name: www482.your-server.de
- IP address: 78.47.237.136
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "ImmunOs Therapeutics"
ImmunOs Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel …See details»
Our Company - Immunostherapy
ImmunOs Therapeutics AG has developed a proprietary human leukocyte antigen (HLA)-based platform to generate a novel class of biologic therapeutics for the treatment of cancer and autoimmune disease.See details»
Management Team - Immunostherapy
Steve Coats has been Chief Development Officer of ImmunOs since December 2021. He has over 25 years of experience as a biopharmaceutical research and development executive, …See details»
ImmunOs Therapeutics AG - LinkedIn
ImmunOs Therapeutics AG Biotechnology Schlieren, Zurich 5,652 followers Novel human immunomodulatory proteins for cancer and autoimmune diseases with a specific role in innate …See details»
Immunos Therapeutics - Overview, News & Similar companies
Oct 24, 2023 ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002 Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 24, …See details»
ImmunOs Therapeutics AG Receives Public Funding from
Apr 12, 2021 For more information, please visit www.immunostherapeutics.com. About ProteoGenix ProteoGenix is a biotech contract research organization (CRO) providing flexible …See details»
ImmunOs Therapeutics AG raises CHF 15M in Series A Financing
Dec 10, 2019 Schlieren (Zurich Area), Switzerland. – December 10, 2019 – ImmunOs Therapeutics AG, a Swiss bio technology company and leading developer of a next generation …See details»
ImmunOs Therapeutics - PitchBook
ImmunOs Therapeutics General Information Description. Developer of novel human immunomodulatory proteins and drugs designed to treat cancer and autoimmune diseases. …See details»
ImmunOs Therapeutics AG Receives Public Funding from Eurostars …
Apr 12, 2021 For more information, please visit www.immunostherapeutics.com About ProteoGenixProteoGenix is a biotech contract research organization (CRO) providing flexible …See details»
Board of Directors - Immunostherapy
Prior to joining MPM, Markus was at Roche, where he served for nearly 20 years in several senior management positions in the Pharma R&D organization, including VP and Director of the …See details»
ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor …
Nov 15, 2021 IOS-1002 is a first-in-class, multi-functional agent based on a naturally occurring human leukocyte antigen (HLA) that interacts with key components of the innate immune …See details»
ImmunOs Therapeutics AG Raises $11 Million and Further …
Sep 17, 2024 Existing investors and new investor Double Point Ventures join forces to support ImmunOs TherapeuticsInvestment secures funding of ongoing promising clinical trial of IOS …See details»
ImmunOs Therapeutics Presents Details of Novel Bispecific
Dec 11, 2023 [email protected]. Media Inquiries akampion Dr. Ludger Wess / Ines-Regina Buth Managing Partners [email protected] Tel. +49 40 88 16 59 64 / Tel. +49 …See details»
Careers - Immunostherapy
We value innovative thinking, an entrepreneurial spirit, teamwork and the ability to work effectively across all departments in the organization. Open positions: We can be reached at: ImmunOs …See details»
ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial
Oct 24, 2023 [email protected]. Media Inquiries akampion Dr. Ludger Wess / Ines-Regina Buth Managing Partners [email protected] Tel. +49 40 88 16 59 64 / Tel. +49 …See details»
ImmunOs Therapeutics Receives Regulatory Approval for First-In …
Jan 17, 2023 - Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors- First patients to be enrolled in Q1, 2023 Schlieren (Zurich …See details»
Approach - Immunostherapy
ImmunOs’ approach is based on the identification of specific human leukocyte antigen (HLA) molecules that hyper-activate the immune system of patients with severe autoimmune disorders.See details»
ImmunOs Therapeutics´ Lead Program Shows Strong Anti-Tumor
Nov 15, 2022 [email protected]. Media Inquiries akampion Dr. Ludger Wess / Ines-Regina Buth Managing Partners [email protected] Tel. +49 40 88 16 59 64 / Tel. +49 …See details»
The Next Generation Pipeline - Immunostherapy
ImmunOs’ HLA-based pipeline includes first-in-class immunotherapies for the treatment of cancer and autoimmune disease. The Company’s immuno-oncology pipeline is based on its ability to …See details»